Skip to main content
. 2015 Nov 17;5:66. doi: 10.1186/s13550-015-0145-8

Fig. 5.

Fig. 5

Time-dependent binding of 68Ga-PSMA-HBED-CC in (a) castration-resistant prostate cancer (CRPC) cells with and without coincubation with abiraterone acetate (AA, 5 μmol/L) and testosterone (T, 1 nmol/L) and (b) in androgen-sensitive revCRPC cells with and without AA-treatment (5 μmol/L) or additional withdrawal of testosterone (−T) from the medium. Displayed is the percentage uptake of applied radioactivity per 106 cells (mean ± SD; n = 9 cultures)